NCT04890483 tDCS in Post-Acute COVID-19 Patients With SARDs
| NCT ID | NCT04890483 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Sao Paulo |
| Condition | Rheumatic Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2021-05-17 |
| Primary Completion | 2024-05-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2021-05-17 with a primary completion date of 2024-05-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Some patients develop "Post-acute COVID-19 syndrome," in which they experience persistent symptoms after recovering from the acute phase of COVID-19 infection. This syndrome may be more significant in patients with systemic autoimmune rheumatic diseases (SARDs) who have been suffering from several symptoms associated to SARDs, such as myalgia, fatigue, and general pains. The transcranial direct current stimulation (tDCS) technique has been frequent, for example, to relieve fatigue and general pains in general population. However, to date, there are no studies evaluating this technique in ARD patients with post-acute COVID-19; therefore, the main objective of the opened study is to evaluate the safety and efficacy of the application of acute tDCS in ARD patients with post-acute COVID-19.
Eligibility Criteria
Inclusion Criteria: * Patients with well-defined ARDs (rheumatoid arthritis, sclerosis systemic, Sjögren syndrome, spondyloarthritis, systemic lupus erythematosus, systemic vasculitis, and systemic autoimmune myopathies) * Fatigue or general pains. Exclusion Criteria: * Neoplasia, using heart pacemarker, using visceral metalic clips, infections (HIV, HTLV-1, hepatitis), pregnance, previous historical of convulsions or epilepsies
Contact & Investigator
Samuel K Shinjo, PhD
PRINCIPAL INVESTIGATOR
Sao Paulo University
Frequently Asked Questions
Who can join the NCT04890483 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Rheumatic Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04890483 currently recruiting?
Yes, NCT04890483 is actively recruiting participants. Contact the research team at samuel.shinjo@usp.br for enrollment information.
Where is the NCT04890483 trial being conducted?
This trial is being conducted at São Paulo, Brazil.
Who is sponsoring the NCT04890483 clinical trial?
NCT04890483 is sponsored by University of Sao Paulo. The principal investigator is Samuel K Shinjo, PhD at Sao Paulo University. The trial plans to enroll 20 participants.